Tuberculosis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:14:35 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Tuberculosis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on High-Dose Rifampicin Safety for Adults with Complex Tuberculosis Using Isoniazid, Pyrazinamide, and Ethambutol Combination https://clinicaltrials.eu/trial/study-on-high-dose-rifampicin-safety-for-adults-with-complex-tuberculosis-using-isoniazid-pyrazinamide-and-ethambutol-combination/ Wed, 29 Apr 2026 15:03:16 +0000 https://clinicaltrials.eu/trial/study-on-high-dose-rifampicin-safety-for-adults-with-complex-tuberculosis-using-isoniazid-pyrazinamide-and-ethambutol-combination/ This clinical trial is focused on studying the safety of using high doses of rifampicin for treating adults with difficult-to-treat tuberculosis (TB). Tuberculosis is an infectious disease that primarily affects the lungs but can also impact other parts of the body, known as extrapulmonary TB. The study will involve the use of Rifampicin 150 mg Capsules, Rifampicin 300 mg Capsules, and a combination medication called RIMSTAR®, which includes isoniazid, pyrazinamide, rifampicin, and ethambutol hydrochloride. These medications are taken orally, meaning they are swallowed.

The purpose of the study is to evaluate the safety of a higher dose of rifampicin, specifically 35 mg per kilogram of body weight per day, when used alongside standard doses of the other medications for eight weeks. The study will monitor participants for any severe side effects, which are referred to as severe adverse events, and compare these findings to historical data from patients who received a lower dose of rifampicin. The trial aims to understand if the higher dose is safe for patients with both pulmonary and extrapulmonary drug-susceptible TB, especially those who are considered difficult to treat due to various health conditions.

Participants in the study will receive either the high-dose rifampicin treatment or a standard treatment, which may include a placebo. The study will last for eight weeks, during which time participants will be closely monitored for any side effects and the effectiveness of the treatment. The trial will also assess how quickly the TB bacteria in the lungs are cleared, as well as any changes in the participants’ quality of life and the costs associated with TB treatment. The study is expected to conclude by September 2026.

]]> Study on the Effects of Tedizolid and Linezolid for Patients with Suspected Lung Tuberculosis https://clinicaltrials.eu/trial/study-on-the-effects-of-tedizolid-and-linezolid-for-patients-with-suspected-lung-tuberculosis/ Wed, 29 Apr 2026 15:00:44 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-tedizolid-and-linezolid-for-patients-with-suspected-lung-tuberculosis/ This clinical trial is focused on studying the effects of certain medications on a lung infection caused by Mycobacterium tuberculosis, commonly known as tuberculosis. The study will evaluate the early effects of two medications, tedizolid and linezolid, on this infection. Additionally, the study will compare these medications to a standard treatment that includes rifampicin, isoniazid, pyrazinamide, and ethambutol. These medications are taken orally, meaning they are swallowed in pill form.

The purpose of the study is to assess how well these medications work in reducing the bacteria in the lungs during the early days of treatment. Participants will take the medications for a period of up to seven days. The study will involve taking samples from the lungs to measure the number of bacteria present at different times during the treatment. This will help determine how quickly the medications are working to reduce the infection.

Throughout the study, the safety and any side effects of the medications will be monitored. The study aims to provide valuable information on the effectiveness of tedizolid and linezolid compared to the standard treatment for tuberculosis. This research could help improve treatment options for people with this lung infection in the future.

]]> Study on the Safety and Tolerability of Higher Dose Rifampicin for Tuberculosis Patients https://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-higher-dose-rifampicin-for-tuberculosis-patients/ Wed, 29 Apr 2026 14:25:28 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-higher-dose-rifampicin-for-tuberculosis-patients/ This clinical trial is focused on studying the disease known as Tuberculosis, which is an infectious disease that primarily affects the lungs. The treatment being tested in this study is a medication called Rifampicin, which is an antibiotic commonly used to treat tuberculosis. The purpose of the study is to evaluate the safety and tolerability of a higher dose of Rifampicin in patients with tuberculosis.

Participants in the study will receive an optimized dose of Rifampicin over a period of six months. The study will monitor the safety of this higher dose by observing the occurrence of liver-related side effects, known as hepatotoxicity, among the participants. The study will also look at other side effects and the overall treatment outcomes at the end of the treatment period.

Throughout the study, participants will be regularly assessed to ensure their safety and to gather information on how their bodies respond to the treatment. The study aims to provide valuable insights into whether a higher dose of Rifampicin can be safely used to improve treatment outcomes for patients with tuberculosis.

]]> Study on Higher Doses of Rifampicin and Pyrazinamide for Shortened Treatment of Mild-to-Moderate Tuberculosis in Patients with Drug-Sensitive Pulmonary TB https://clinicaltrials.eu/trial/study-on-higher-doses-of-rifampicin-and-pyrazinamide-for-shortened-treatment-of-mild-to-moderate-tuberculosis-in-patients-with-drug-sensitive-pulmonary-tb/ Wed, 29 Apr 2026 14:22:58 +0000 https://clinicaltrials.eu/trial/study-on-higher-doses-of-rifampicin-and-pyrazinamide-for-shortened-treatment-of-mild-to-moderate-tuberculosis-in-patients-with-drug-sensitive-pulmonary-tb/ This clinical trial is focused on studying tuberculosis, a disease that primarily affects the lungs and is caused by bacteria. The study is investigating the use of higher doses of two antibiotics, rifampicin and pyrazinamide, to see if they can effectively shorten the treatment duration for patients with mild-to-moderate tuberculosis. These medications are taken orally, meaning they are swallowed in pill form.

The purpose of the study is to explore whether a shorter treatment period with higher doses of these medications can be safe and effective for patients with drug-sensitive pulmonary tuberculosis. Participants in the study will receive either the higher doses of the medications or the standard treatment. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects.

Throughout the study, participants will be monitored to assess how their bodies process the medications and to ensure their safety. The study will last for a period of up to four months, during which time participants will have regular check-ups and tests to track their progress and any side effects. The goal is to find a more efficient way to treat tuberculosis, potentially reducing the time patients need to be on medication.

]]>